HekeTiss successfully completed its first full GMP-compliant production of TrophiPatch on November 25, 2024, in collaboration with the Plateforme des laboratoires de thérapie cellulaire et de transplantation of the University Hospitals of Geneva (HUG).

This milestone confirms the robustness and reproducibility of the manufacturing process under Good Manufacturing Practice (GMP) conditions, ensuring that TrophiPatch meets the required quality and regulatory standards for clinical use.

The establishment of a fully compliant production workflow represents a critical step in the clinical development of TrophiPatch and supports the initiation of patient treatment within the RESCUE-PATCH clinical trial.